Chen Fang's incident is just a small episode

With Chen Xia's strong rise, the people around him also rose to heaven, and the changes took place in Qingfeng Village, and the fate of many people changed.

However, Chen Xia did not understand the negative problems caused by the poor's sudden wealth before, so this time he decided to sort them out while the Chinese New Year.

Money is a good thing, but it can also become a bad thing.

I wonder if Chen Xia would regret founding Four Seasons Group one day and regretting having so much money. Then he said that his happiest day was when he earned more than 100 yuan a month at Yuezhou Hospital?

Chen Xia, who thought money was a bad thing, started to be busy making money again in the next few days.

Hoho, man!

The news that Siji Group decided to open up five antibiotic patents has spread all over the world in an instant with the announcement of the WHO.

Look, all pharmaceutical companies of all sizes around the world gather in Xiangjiang.

The WHO considers the very long term that their requirement is to allocate the number of patent authorized pharmaceutical companies based on "continents".

Look at the patent authorizations that Chen Xia had done in the past. His approach was to arrange a leading pharmaceutical company on one continent, and then we all set up a price alliance together.

The drugs produced by major pharmaceutical companies after obtaining patent authorization are only circulated and sold in their respective continents, and they promise to not infringe on each other's market, so as to maintain a high selling price and high profit.

The fact is indeed as Chen Xia expected, this "alliance" formed by four pharmaceutical companies, including Pumpkin Vine Pharmaceutical, Pfizer Pharmaceutical, Takeda Pharmaceutical and GlaxoSmithKline, has achieved great success.

Each company's sales exceeded 10 billion yuan, and its profits reached an astonishing $7 billion.

At the same time, Chen Xia also used the connections and relationships of these three major pharmaceutical giants to quickly build Four Seasons Group into a "giant".

He also achieved the goal of having me and I have you through his participation in the three major pharmaceutical companies, and he truly turned the four companies into an "interest group".

Of course, the WHO has seen this disadvantage, so they have made a way to allocate seats according to continents for this "interest group".

In this way, those small and medium-sized pharmaceutical companies will have the opportunity to make a comeback.

For example, if you have experienced many hardships in North America, but I have three places in Africa, and you can’t take care of me, then my small African pharmaceutical company will have the opportunity.

The WHO not only wants to support small and medium-sized pharmaceutical companies, but also break the monopoly of the "unicorn group",

There is also another purpose, which is to have more authorized pharmaceutical companies, so that there will be more competition, prices will be reduced, and it can benefit more people.

Unfortunately, the WHO was worried about publicly authorizing the patent that was exchanged for the threats and induces Siji Group, and the result would be satisfactory?

Look at the Pumpkin Vine Pharmaceuticals.

Didn’t Chen Xia think that he would control his patents, produce them, export them, and sell them by himself? He would earn more profits?

But do you have this "channel"?

When you produce drugs, you need to distribute them to hospitals, pharmacies and other sales terminals in various regions. You need a strong and efficient logistics network, and at the same time, you need a large number of "medical representatives" to promote them.

With this condition, it is definitely not something that a small factory or one person can handle.

If the channel is not in your own hands, you do not have the ability to fully distribute the goods. So what if you have a patent?

Do you have sales channels in your own country?

If you want to export abroad, do you have such a social network that can allow you to successfully pass the review and approval of the health and drug regulatory departments of other countries?

At that time, Pumpkin Vines had no such "channel" and could not enter those developed countries, so they could only earn patent fees and dividends through cooperation.

Even pumpkin vines can’t do it. Why can those African pharmaceutical companies and South American pharmaceutical companies do it?

So in the end, the big pharmaceutical companies have mastered all sales channels and are still in an absolute monopoly position. At most, they just give these small pharmaceutical companies some soup.

This is why "the strong are stronger".

The WHO's wishes are good, and the ideals are full, but unfortunately the reality is skinny.

Why does Chen Xia attach great importance to "channels"?

Longfeng Pharmacy, Watsons, Bajia Supermarket, Fengze Electrical Appliances, Four Seasons Cinema, Yuezhou Small Commodity City, Clothing City, Light Textile City, etc., and even the newly built "Four Seasons Center" is not a "channel"?

This is also the reason. If you want to sell your own products without being controlled by others, you must have your own channels.

The slogan "channel is king" will never be outdated.

Xiangjiang Central Ring Road, Sisy Group Headquarters Building, is located in the 38th floor of the building.

The Four Seasons Group Antibiotic Patent Authorization Bidding Conference was held here, and the WHO also sent representatives to attend the bidding conference.

The bidding rules are very simple, each continent has 3 places.

Among them, Pumpkin Vine Pharmaceutical's three allies: Pfizer, Takeda, and GlaxoSmithKline naturally hold a quota, which always takes care of one's own people and is awarded according to the previous patent fees.

As for other pharmaceutical factories, the patent fees start at 5%. Everyone bids together. Whoever gives the higher patent fees will get this valuable place.

It must be valuable, but the market for application of antibiotics is too broad.

Inside and outside pediatric ENT departments, most diseases are needed in every department.

From a clinical point of view, this latest and excellent antibiotic application can save many lives, and life is priceless.

From the perspective of pharmaceutical companies, if you use more clinically, you will have higher sales and higher profits. This is not something that can be compared with gastritis and cold medicines or anti-rejection drugs.

Everyone knows that whoever owns an antibiotic patent means who gets a treasure pot, so everyone wants to miss it.

As the boss, Chen Xia certainly would not participate in the auction in person, he was watching coldly.

Other continents are not bad, but within Asia, he does not want Southeast Asia's "Three Buddhas" and the three countries of Afghanistan to obtain patent rights.

The Three Buddhas will massacre Chinese in 1998. This inferior nation and inferior country do not deserve the patented medicine of pumpkin vine.

A Sanguo is too dishonest in his business and is proficient in cheating and cheating. In the future, Chen Xia doesn't have to want to get a penny patent from A San.

It would be useless to reclaim the patent of Pumpkin Vines by then. In terms of drug imitation, A Sanguo is definitely the world NO1, and you can't even ban it.

The final result also made Chen Xiada feel relieved. In addition to Japan's Takeda Pharmaceutical, the other two were won by Korean and American Pharmaceuticals in Bangzi Country and Usa Pharmaceuticals in Baotou Country.

The patent fee given by Usa Kingdom is as high as 20%. The big dogs are not short of money at all. There is too much oil underground. They invest in pharmaceutical factories mainly for the needs of industrial layout and do not value immediate interests.

Of course this is an exception. For example, the patent fee for South Korea and the United States Pharmaceuticals is only 10%.

The other continents are similar, basically hovering around 10%. Chen Xia's old friend, Switzerland's Novartis Pharmaceutical, also grabbed one of the places.

If nothing unexpected happens, these five antibiotics can generate US$2.5 to 3 billion in revenue for the Four Seasons Group every year.
Chapter completed!